Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PSNL

Personalis Inc

Sep 12 • 04:00PM ET

5.85

-0.25 -4.10 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN NTRA CDNA GH FLGT BNR EXAS FATE TXG MYGN

| Held by: ARKG VTI IWM VXF IWN IBB VTWO VFMO DFAS DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.27	Insider Own	40.29%	Shs Outstand	88.65M	Perf Week	11.64%
Market Cap	518.78M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	-0.01%	Shs Float	53.09M	Perf Month	21.12%
Enterprise Value	388.81M	PEG	-	EPS next Q	-0.28	Inst Own	43.43%	Short Float	15.34%	Perf Quarter	0.69%
Income	-91.32M	P/S	6.46	EPS this Y	29.56%	Inst Trans	17.68%	Short Ratio	6.41	Perf Half Y	63.87%
Sales	80.32M	P/B	2.72	EPS next Y	4.27%	ROA	-41.12%	Short Interest	8.15M	Perf YTD	1.21%
Book/sh	2.15	P/C	2.99	EPS next 5Y	17.18%	ROE	-60.26%	52W High	7.79 -24.90%	Perf Year	1.39%
Cash/sh	1.95	P/FCF	-	EPS past 3/5Y	2.63% -11.31%	ROIC	-40.58%	52W Low	2.83 106.99%	Perf 3Y	86.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-0.34% 5.35%	Gross Margin	31.45%	Volatility	7.05% 5.81%	Perf 5Y	-72.12%
Dividend TTM	-	EV/Sales	4.84	EPS Y/Y TTM	22.13%	Oper. Margin	-89.64%	ATR (14)	0.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.92	Sales Y/Y TTM	0.36%	Profit Margin	-113.70%	RSI (14)	63.05	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	6.07	EPS Q/Q	7.25%	SMA20	16.79%	Beta	1.79	Target Price	7.06
Payout	-	Debt/Eq	0.23	Sales Q/Q	-23.81%	SMA50	5.41%	Rel Volume	0.79	Prev Close	6.10
Employees	229	LT Debt/Eq	0.18	Earnings	Aug 05 AMC	SMA200	19.40%	Avg Volume	1.27M	Price	5.85
IPO	Jun 20, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.17% -14.47%	Trades		Volume	1,006,890	Change	-4.10%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Initiated	Guggenheim	Buy	$6
Mar-17-25	Initiated	Craig Hallum	Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy	$8
Feb-06-23	Upgrade	Needham	Hold → Buy
Jan-07-22	Upgrade	BofA Securities	Neutral → Buy	$27 → $23
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-03-21	Downgrade	Needham	Buy → Hold
Oct-15-21	Resumed	Cowen	Outperform
Sep-20-21	Reiterated	Needham	Buy	$33 → $28
May-06-21	Upgrade	Oppenheimer	Perform → Outperform	$28
Jan-28-21	Initiated	Truist	Buy	$50
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral	$40
Nov-12-20	Reiterated	Needham	Buy	$25 → $32
Nov-06-20	Downgrade	Oppenheimer	Outperform → Perform
Oct-19-20	Initiated	Citigroup	Buy	$35
Oct-08-20	Initiated	BTIG Research	Buy	$35
Aug-27-20	Initiated	H.C. Wainwright	Buy	$30
Aug-18-20	Initiated	Needham	Buy	$25
Sep-26-19	Upgrade	BofA/Merrill	Neutral → Buy	$22
Jul-15-19	Initiated	Oppenheimer	Outperform	$29

Show Previous Ratings

Sep-11-25 08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks) +13.17%
Sep-10-25 04:05PM	CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test (Business Wire)
Sep-03-25 04:05PM	Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing (Business Wire)
Aug-27-25 04:01PM	Personalis to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 09:35AM	Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) (Zacks) +5.69%
09:35AM	Loading…
Aug-12-25 09:35AM	After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) (Zacks)
Aug-08-25 12:00PM	All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy (Zacks)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-05-25 04:10PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance) -21.90%
04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-04-25 09:58AM	Earnings To Watch: Personalis Inc (PSNL) Reports Q2 2025 Result (GuruFocus.com)
Jul-22-25 04:01PM	Personalis to Announce Second Quarter 2025 Financial Results (Business Wire) +5.13%
Jul-18-25 04:00PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
Jul-09-25 04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
07:08AM	Loading…
Jul-03-25 07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-17-25 10:40AM	Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-13-25 12:07PM	Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach (Zacks)
Jun-03-25 04:00PM	Personalis' NeXT Personal Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO (Business Wire) +5.53%
Jun-02-25 04:00PM	New Data Shows NeXT Personal Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse (Business Wire)
May-22-25 06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection (Business Wire)
May-14-25 04:01PM	Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference (Business Wire) -6.23%
May-07-25 03:23AM	Personalis Inc (PSNL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com) +21.00%
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.10%
04:01PM	Personalis Reports First Quarter 2025 Financial Results (Business Wire)
May-05-25 10:12AM	Personalis Inc (PSNL) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-30-25 08:05PM	Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates (Zacks)
Apr-28-25 05:00PM	Personalis' NeXT Personal Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study (Business Wire)
Apr-22-25 06:47PM	Is Personalis, Inc. (PSNL) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey) +7.91% +7.92%
04:01PM	Personalis to Announce First Quarter 2025 Financial Results (Business Wire)
06:00AM	Loading…
06:00AM	Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection (Business Wire)
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 04:01PM	Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-03-25 06:00AM	New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection (Business Wire)
Feb-28-25 04:00AM	Personalis Inc (PSNL) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:20PM	Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.36%
04:21PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:09AM	Personalis Inc (PSNL) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com) +5.91%
Feb-20-25 10:00AM	Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) -6.78%
Feb-18-25 04:01PM	Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference (Business Wire) +9.62%
Feb-13-25 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results (Business Wire) +7.08% +10.42%
Jan-28-25 04:01PM	Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire) -6.37% -7.90%
Jan-20-25 12:00PM	Personalis (PSNL) Upgraded to Buy: Here's Why (Zacks)
Jan-13-25 11:09AM	Researchers find ctDNA test predicts lung cancer outcomes in study (Medical Device Network)
05:00AM	New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer (Business Wire)
Jan-07-25 04:01PM	Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue (Business Wire) -6.71% -6.35%
Dec-21-24 07:30AM	Personalis price target raised to $8 from $7 at BTIG (TipRanks)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) +9.32%
Dec-19-24 09:00AM	Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna (Business Wire) +47.75%
Dec-18-24 03:00AM	Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma (Insider Monkey) -7.29%
Dec-16-24 08:00AM	Personalis and Tempus Expand Collaboration to Biopharma (Business Wire)
Nov-20-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -6.23%
Nov-07-24 10:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid Strategic ... (GuruFocus.com) -22.58%
Nov-06-24 05:25PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Personalis: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 04:01PM	Personalis to Present at the Stifel 2024 Healthcare Conference (Business Wire) +12.80%
08:01AM	Personalis Inc (PSNL) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-23-24 04:01PM	Personalis to Announce Third Quarter 2024 Financial Results (Business Wire)
Sep-16-24 09:00AM	ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal MRD Test (Business Wire)
Aug-22-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire) -9.94%
Aug-21-24 06:13PM	Why Tempus AI Stock Skyrocketed Nearly 22% Today (Motley Fool) +11.42%
Aug-19-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-16-24 08:30AM	Personalis and Tempus Announce Expanded Collaboration (Business Wire) +18.15%
Aug-13-24 09:15AM	Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.12%
Aug-07-24 05:30PM	Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.00% +19.10%
04:35PM	Personalis: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 04:05PM	Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% (GlobeNewswire)
Jul-31-24 04:01PM	Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference (Business Wire) +10.58%
Jul-24-24 04:01PM	Personalis to Announce Second Quarter 2024 Financial Results (Business Wire)
Jul-11-24 09:00AM	Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing (GlobeNewswire) +9.68%
Jun-18-24 04:01PM	Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference (Business Wire)
Jun-13-24 08:00AM	Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call (Business Wire)
Jun-04-24 04:05PM	ASCO Data Highlights NeXT Personal Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring (Business Wire) -6.90% +8.89%
May-31-24 09:05AM	Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus (Business Wire)
May-22-24 09:05AM	Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 (Business Wire) +7.24%
May-17-24 04:05PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-24 12:31PM	Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.43%
07:11AM	Q1 2024 Personalis Inc Earnings Call (Thomson Reuters StreetEvents)
04:00AM	Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ... (GuruFocus.com)
May-08-24 08:59PM	PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:22PM	Personalis: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 04:01PM	Personalis to Announce First Quarter 2024 Financial Results (Business Wire) -5.80%
Mar-28-24 04:01PM	Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
09:00AM	Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-26-24 09:00AM	Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring (Business Wire)
Mar-19-24 04:43PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.79%
Feb-29-24 09:44AM	Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.16%
Feb-28-24 05:00PM	Personalis: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Personalis Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-14-24 04:01PM	Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +10.46%
Jan-31-24 04:01PM	Personalis to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-24 09:00AM	Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology (Business Wire) -8.50%
Jan-17-24 04:15PM	Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.06% -7.43%
Jan-16-24 09:05AM	Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay (Business Wire) -5.17%
Jan-05-24 09:05AM	Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance (Business Wire) +7.00%

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jul 28 '25	Sale	6.57	452	2,970	124,505	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	Jul 28 '25	Sale	6.57	641	4,211	164,458	Jul 30 04:20 PM
Tachibana Aaron	CFO AND COO	May 16 '25	Sale	4.95	1,291	6,390	165,099	May 20 05:53 PM
Moore Stephen Michael	SVP and Chief Legal Officer	May 16 '25	Sale	4.95	1,675	8,291	64,200	May 20 05:51 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	May 16 '25	Sale	4.95	910	4,504	124,957	May 20 05:50 PM
Tachibana Aaron	CFO AND COO	Jan 28 '25	Sale	5.79	708	4,099	166,390	Jan 30 05:01 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Jan 28 '25	Sale	5.79	519	3,005	123,367	Jan 30 04:59 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Dec 16 '24	Sale	3.82	4,834	18,466	123,886	Dec 18 04:35 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Dec 16 '24	Sale	3.82	1,513	5,780	65,875	Dec 18 04:30 PM
Tachibana Aaron	CFO AND COO	Dec 16 '24	Sale	3.82	6,865	26,224	167,098	Dec 18 04:25 PM
Tachibana Aaron	CFO AND COO	Nov 18 '24	Sale	3.79	1,307	4,954	173,963	Nov 20 04:19 PM
Moore Stephen Michael	SVP and Chief Legal Officer	Nov 18 '24	Sale	3.79	1,693	6,416	67,388	Nov 20 04:17 PM
Chen Richard	CHIEF MEDICAL OFFICER AND EVP	Nov 18 '24	Sale	3.79	921	3,491	128,720	Nov 20 04:14 PM
Hall Christopher M	PRESIDENT AND CEO	Nov 01 '24	Sale	5.38	26,443	142,263	178,098	Nov 05 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSNL

Personalis Inc

Upgrade your FINVIZ experience